BioCentury | May 10, 2004
Company News

Immerge BioTherapeutics Inc., Infigen other research news

...heterozygous pigs. Immerge is a joint venture between Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) and BioTransplant Inc....
BioCentury | Oct 13, 2003
Company News

BioTransplant, Miltenyi Biotec deal

...for Chapter 11, said the deal is subject to approval of the U.S. Bankruptcy Court. BioTransplant Inc....
BioCentury | Jun 30, 2003
Clinical News

BioTransplant, MedImmune Inc. preclinical data

...in psoriasis, the indication for which it is in Phase II (see BioCentury, April 28). BioTransplant Inc....
BioCentury | Jun 16, 2003
Clinical News

BioTransplant, Novartis preclinical data

...of antibody-mediated rejection. Data were presented at the American Transplant Congress meeting in Washington, D.C. BioTransplant Inc....
BioCentury | Jun 9, 2003
Company News

BioTransplant, Miltenyi Biotec deal

...for Chapter 11, said the deal is subject to approval of the U.S. Bankruptcy Court. BioTransplant Inc....
BioCentury | May 12, 2003
Company News

Osiris management update

...therapy Hired: James Embree as SVP of operations, formerly SVP of manufacturing and development at BioTransplant...
BioCentury | Apr 28, 2003
Clinical News

Siplizumab: Phase II

...completion of a Phase II psoriasis trial of Vitaxin, MEDI's monoclonal antibody against integrin alpha(v)-beta(3). BioTransplant Inc....
BioCentury | Apr 7, 2003
Company News

BioTransplant, Catholic University of Louvain antibodies, autoimmune/inflammation, transplant news

...BioCentury, Oct. 28, 2002). BTRN is reorganizing under Chapter 11 of the U.S. Bankruptcy Code. BioTransplant Inc....
BioCentury | Mar 17, 2003
Tools & Techniques

Sizing up the psoriasis market

...Johnson Remicade infliximab TNF alpha inhibitor Ph II Schering-Plough MedImmune Siplizumab Anti-CD2 antibody Ph II BioTransplant...
BioCentury | Feb 3, 2003
Company News

BioTransplant, Catholic University of Louvain deal

...AG (NVS; SWX:NOVN, Basel, Switzerland) a sublicense to MEDI-507 for use with a xenotransplantation system. BioTransplant Inc....
Items per page:
1 - 10 of 142
BioCentury | May 10, 2004
Company News

Immerge BioTherapeutics Inc., Infigen other research news

...heterozygous pigs. Immerge is a joint venture between Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) and BioTransplant Inc....
BioCentury | Oct 13, 2003
Company News

BioTransplant, Miltenyi Biotec deal

...for Chapter 11, said the deal is subject to approval of the U.S. Bankruptcy Court. BioTransplant Inc....
BioCentury | Jun 30, 2003
Clinical News

BioTransplant, MedImmune Inc. preclinical data

...in psoriasis, the indication for which it is in Phase II (see BioCentury, April 28). BioTransplant Inc....
BioCentury | Jun 16, 2003
Clinical News

BioTransplant, Novartis preclinical data

...of antibody-mediated rejection. Data were presented at the American Transplant Congress meeting in Washington, D.C. BioTransplant Inc....
BioCentury | Jun 9, 2003
Company News

BioTransplant, Miltenyi Biotec deal

...for Chapter 11, said the deal is subject to approval of the U.S. Bankruptcy Court. BioTransplant Inc....
BioCentury | May 12, 2003
Company News

Osiris management update

...therapy Hired: James Embree as SVP of operations, formerly SVP of manufacturing and development at BioTransplant...
BioCentury | Apr 28, 2003
Clinical News

Siplizumab: Phase II

...completion of a Phase II psoriasis trial of Vitaxin, MEDI's monoclonal antibody against integrin alpha(v)-beta(3). BioTransplant Inc....
BioCentury | Apr 7, 2003
Company News

BioTransplant, Catholic University of Louvain antibodies, autoimmune/inflammation, transplant news

...BioCentury, Oct. 28, 2002). BTRN is reorganizing under Chapter 11 of the U.S. Bankruptcy Code. BioTransplant Inc....
BioCentury | Mar 17, 2003
Tools & Techniques

Sizing up the psoriasis market

...Johnson Remicade infliximab TNF alpha inhibitor Ph II Schering-Plough MedImmune Siplizumab Anti-CD2 antibody Ph II BioTransplant...
BioCentury | Feb 3, 2003
Company News

BioTransplant, Catholic University of Louvain deal

...AG (NVS; SWX:NOVN, Basel, Switzerland) a sublicense to MEDI-507 for use with a xenotransplantation system. BioTransplant Inc....
Items per page:
1 - 10 of 142